

# Expense Reimbursement Form



To be completed by Meeting Participant in BLOCK capitals or electronically. If completed electronically, the form must be printed and a hardcopy signed. For further guidance how to fill in this form, please refer to the Thank you letter email.

Country of Residence  
(please select before printing)

France

Meeting Name  
Date & Location

EMEA EZEZ & EKBG Meeting  
January 2026, London

Participant Name

SOUAD BEZZEGHOUD

Participant Full Address

(Street, House/Apartment number, Postal/ZIP Code, City)

12 RUE DU PONTIN, 42230 ROCHE LA MOLIERE, LOIRE (FRANCE)

Local Transportation:

0,5 EUR/km, max amount of 300 EUR, NO GASOLINE

DISTANCE FROM HOME TO AIRPORT (88.3 KM EACH WAY, ROUND TRIP X2) = 0,5 x (88,3 x 2)

EUR 88,300

PARKING AIRPORT PARKING FEES

EUR 80,900

UK ETA (Electronic Travel Authorization)

EUR 19,080

x

EUR =

Meals & Drinks are not eligible for reimbursement

EVENING DINNER 13JAN2026 at Hotel Park Plaza Westminster (No information provided about the dinner program available on the evening of January 13 (see attached))

EUR 32,390

Total amount: EUR 189€

BANK Details for payment

Bank name

LA BANQUE POSTALE ORLEANS LA SCE CENTRE FINANCIER

Account Holder

SOUAD BEZZEGHOUD

IBAN/Bank account number

FR30 2004 1010 1263 5752 6V03 307

BIC/SWIFT

P S S T F R P P S C E

TAX ID- RPPS number or Siret/Siren

NOT APPLICABLE

Lilly is unable to reimburse any personal expenses, such as mobile charges, minibar, or entertainment.

Please ensure that all reasonable expenses, except for mileage claims, are accompanied by ORIGINAL RECEIPTS. It is acceptable to scan and email receipts.

PLEASE RETURN this form with your scanned receipts to the email address provided below. Your expenses will only be paid if this claim is satisfactorily completed, signed, and returned within 90 days of the meeting date.

EMS C2P FR@lilly.com

#### Privacy Notice and Consent

I confirm to the best of my knowledge and belief, all the information provided above is true and correct.

I hereby give my consent for the use of my personal information, which includes my Basic Personal Details (Name, Address); Financial Information (Bank Account Information); Personal Contact Information (Email Address); and Travel & Expense Details (expense details), for the administration of our business processes, namely the Reimbursement of Expenses, in accordance with the conditions provided in the Privacy Statement below. Your PI may be transferred and processed by and between Eli Lilly and Company, its affiliates and wholly-owned subsidiaries and Third parties world wide.

For more information about Lilly's privacy practices, please refer to the Privacy Statement at

Privacy notice

France

I acknowledge that I have received and had the opportunity to review the full privacy policy concerning how my personal information will be used by Lilly, what my rights are with respect to such processing, and have received information on how to contact Lilly should I have any questions regarding such processing. I understand that I have the right to withdraw my consent at any time by contacting Lilly using the information provided in the Privacy Statement. Withdrawal of consent does not affect the lawfulness of processing based on consent before its withdrawal.

BEZZEGHOU SOUAD

Name (printed)

Signature

Date

26 JAN 2026

#### Lilly Administrative information - FOR OFFICE USE ONLY

Prism IO:	P02151877200	Cost Element	4870	Cost Centre	2000196
Mercury Meeting ID:	M-M296020GB25				

**MOVE-Lp(a) INVESTIGATOR ENGAGEMENT MEETING – EMEA SESSION 1  
J2O-MC-EKBG**

Park Plaza Westminster Bridge, London, England

**AGENDA**

Day 1	<b>Monday 12 January 2026</b>
<b>15:00 – 15:10</b>	<b>Agenda and Logistics Review</b> Crystal Steiner, Global Clinical Development Trial Lead
<b>15:10 – 15:15</b>	<b>Welcome</b> Angie Bethel, Vice President & Head of Global Brand Development, Cardiometabolic Health Stephen Nicholls, MBBS, PhD, Global PI & EC Member Amy Ford, Associate Vice President, Clinical Development
<b>15:15 – 16:00</b>	<b>Lp(a) Landscape &amp; Muvalaplin Phase 2 Data</b> Stephen Nicholls, MBBS, PhD, Global PI & EC Member
<b>16:00 – 16:25</b>	<b>Muvalaplin Origins Story</b> Laura Michael, Associate VP, Cardiovascular & Diabetes Metabolic Research
<b>16:25 – 16:45</b>	<b>Challenges to Successful Completion of the MOVE-Lp(a) Trial</b> Stephen Nicholls, MBBS, PhD, Global PI & EC Member
<b>16:45 – 17:05</b>	<b>The Critical Importance of Event Reporting</b> Venu Menon, Clinical Events Committee, C5Research
<b>17:05 – 17:25</b>	<b>Panel Discussion with Q&amp;A</b> Angie Bethel, Vice President & Head of Global Brand Development, Cardiometabolic Health Laura Michael, Associate VP, Cardiovascular & Diabetes Metabolic Research Stephen Nicholls, MBBS, PhD, Global PI & EC Member Venu Menon, Clinical Events Committee, C5Research
<b>17:25 – 17:35</b>	<b>Location Change for Photo</b>
<b>17:35 – 17:50</b>	<b>Group Photo</b>
<b>17:50 – 19:00</b>	<b>Break</b>
<b>19:00 – 19:30</b>	<b>Drinks Reception</b>
<b>19:30 – 21:30</b>	<b>Welcome Dinner</b>

**MOVE-Lp(a) INVESTIGATOR ENGAGEMENT MEETING – EMEA SESSION 1  
J2O-MC-EKBG**

Park Plaza Westminster Bridge, London, England

**Day 2**

**Tuesday 13 January 2026**

<b>6:30 – 7:50</b>	<b>Breakfast</b>
<b>8:00 – 8:05</b>	<b>Welcome &amp; Logistics</b> Crystal Steiner, Global Clinical Development Trial Lead
<b>8:05 – 9:05</b>	<b>Protocol Overview</b> Yuer Yan, MD, PhD, Sr. Director, Clinical Research Physician Elena Tomaselli Muensterman, PharmD, PhD, Director, Clinical Research Scientist
<b>9:05 – 9:20</b>	<b>Trial Status: Recruitment and Operations Overview</b> Crystal Steiner, Global Clinical Development Trial Lead
<b>9:20 – 9:35</b>	<b>Panel Discussion with Q&amp;A</b> Yuer Yan, MD, PhD, Sr. Director, Clinical Research Physician Elena Tomaselli Muensterman, PharmD, PhD, Director, Clinical Research Scientist Crystal Steiner, Global Clinical Development Trial Lead Stephen Nicholls, MBBS, PhD, Global PI & EC Member
<b>9:35 – 10:05</b>	<b>Retention: Screening and Maintaining Participants</b> Christopher Reed, Clinical Development Trial lead Denise Mason, Project Manager, C5Research Grace Tercek, Project Manager, C5Research
<b>10:05 – 10:15</b>	<b>Overview of Rotating Stations and Country Workshop Breakouts</b> Agustin Maschio, Global Clinical Development Trial Lead
<b>10:15 – 10:30</b>	<b>Break/Location Change</b>
<b>10:30 – 12:30</b>	<b>Rotating Stations</b> (Veeva eDC*, IWRS and Product Delivery Overview*, JUDI, Adjudication*, Retention Guide*, Vendor Suite) <b>Austria, Belgium, Czech Republic, France</b>  <b>Country Breakout Workshops</b> (Country Sessions, Medical Q & A, NL Panel Discussion) <b>Germany, Greece, Hungary, Poland</b>
<b>12:30 – 13:20</b>	<b>Lunch</b>
<b>13:30 – 15:30</b>	<b>Rotating Stations</b> (Veeva eDC*, IWRS and Product Delivery Overview*, JUDI, Adjudication*, Retention Guide*, Vendor Suite) <b>Germany, Greece, Hungary, Poland</b>  <b>Country Breakout Workshops</b> (Country Sessions, Medical Q & A, NL Panel Discussion) <b>Austria, Belgium, Czech Republic, France</b>

Lp Next page

MOVE-LP(a) INVESTIGATOR ENGAGEMENT MEETING – EMEA SESSION 1  
J20-MC-EK8G

Park Plaza Westminster Bridge, London, England

15:30 – 15:35	Break/Location Change
15:35 – 15:55	National Leader Panel All Countries Workshop Summary
15:55 – 16:00	Closing

No Dine??

Strongly recommend